IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2473
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$458M
Markus Warmuth
Monte Rosa Therapeutics, Inc. engages in the development of novel small molecule precision medicines. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$GLUE Monte Rosa Therapeutics, Inc. | 47 | 37 | 41 | 90 | - | - | -6.7% | -3.6% | 100.0% | -140.3% | -117.2% | 171.9% | 0.0% | 87.0x | $458M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
Monte Rosa Therapeutics, Inc. (GLUE) receives a "Reduce" rating with a composite score of 47.1/100. It ranks #2473 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Markus Warmuth
Chief Executive Officer
Labor Force
90
37
24
44
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for GLUE
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for GLUE.
View All RatingsHigh margin volatility — erratic forensic earnings quality
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 37 | 15 | +22ALPHA |
| MOMENTUM | 90 | 94 | -4NEUTRAL |
| VALUATION | 41 | 20 | +21ALPHA |
| INVESTMENT | 24 | 9 | +15ALPHA |
| STABILITY | 44 | 24 | +20ALPHA |
| SHORT INT | 16 | 1 | +15ALPHA |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROE proxy -6.7% (sector -2.5%)
GM 100% vs sector 43%, OM -140% vs sector 1%
Capital turnover N/A, R&D intensity 82.3%
Rev growth 172%, 5yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Monte Rosa Therapeutics, Inc. receives a Reduce rating from our analysis, with a composite score of 47.1/100 and 2 out of 5 stars, ranking #2473 out of 7,333 stocks. GLUE's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
GLUE's quality score of 37/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -6.7% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -117.2% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, GLUE appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 5.89x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
Monte Rosa Therapeutics, Inc.'s investment score of 24/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 171.9% vs. a sector average of 5.9% and a return on assets of -3.6% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
Monte Rosa Therapeutics, Inc. (GLUE) is exhibiting exceptional momentum with a score of 90/100, placing it among the strongest trending stocks in the market. Revenue growth stands at 171.9% year-over-year, while a beta of 0.90 reflects its sensitivity to broader market moves. Stocks with momentum scores this high have historically outperformed over the following 3–12 months, suggesting GLUE may continue to benefit from strong institutional interest and positive price trends.
GLUE's stability score of 44/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 0.90 and a debt-to-equity ratio of 87.00x (sector avg: 0.2x). Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
Monte Rosa Therapeutics, Inc.'s short interest score of 16/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include elevated leverage (D/E: 87.00x), small-cap liquidity risk. At $458M (small-cap), GLUE carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
Monte Rosa Therapeutics, Inc. is a small-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2473 of 7,333 overall (66th percentile). Key comparisons include ROE of -6.7% trailing the -2.5% sector median and operating margins of -140.3% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While GLUE currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Short Int. (16) would have the largest impact on the composite score.
ROE 168% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 10978% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate Monte Rosa Therapeutics, Inc. (GLUE) as a Reduce with a composite score of 47.1/100 at a current price of $19.19. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in momentum (90th percentile) and stability (44th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (24th percentile) and quality (37th percentile) tempers our overall conviction. We assign a Narrow Moat rating (44/100), High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
Monte Rosa Therapeutics, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 47.1/100 places it at rank #2473 in our full 7,333-stock universe. At $458M in market capitalization, Monte Rosa Therapeutics, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
The near-term outlook is constructive, with revenue growing at 172% and momentum in the 90th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 24th percentile indicates reinvestment patterns that investors should monitor for sustainability.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -140% (-141.6pp vs sector) and net margins of -117.2%, yielding a gross-to-net conversion rate of -117%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $19.19, Monte Rosa Therapeutics, Inc. is trading near fair value based on current fundamentals. Our value factor score of 41/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 5.9x, P/S of 11.1x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 172% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
Positive momentum (90th percentile) indicates institutional accumulation and favorable technical dynamics that tend to persist in the intermediate term.
The Reduce rating (composite 47.1/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -117.2% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to Monte Rosa Therapeutics, Inc.. Key risk factors include current negative profitability (net margin -117.2%), the combination of leverage (87% D/E) and thin margins (-117.2% net) amplifies downside risk. The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -117.2%); the combination of leverage (87% D/E) and thin margins (-117.2% net) amplifies downside risk. Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 44th percentile and quality factor at the 37th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate Monte Rosa Therapeutics, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-6.7%), negative profitability, weak asset returns (ROA -3.6%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Monte Rosa Therapeutics, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, Monte Rosa Therapeutics, Inc. receives a Reduce rating with a composite score of 47.1/100 (rank #2473 of 7,333). Our quantitative framework assigns a Narrow Moat (44/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 47/100.
Our analysis does not support a constructive view on Monte Rosa Therapeutics, Inc. at this time. The combination of the current quantitative profile, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We assign Monte Rosa Therapeutics, Inc. a Narrow Moat rating with a composite moat score of 44/100. The company possesses identifiable competitive advantages, though they are less entrenched than those of wide-moat peers. Our analysis indicates that Monte Rosa Therapeutics, Inc. can sustain above-average returns on invested capital for at least 10 years, with the strongest contributor being growth durability at 15.8/20.
The strongest moat sources are growth durability (15.8/20) and margin superiority (10.4/20). Rev growth 172%, 5yr history. GM 100% vs sector 43%, OM -140% vs sector 1%. These pillars form the core of Monte Rosa Therapeutics, Inc.'s competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (4.4/20) and financial resilience (6.5/20). ROE proxy -6.7% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect Monte Rosa Therapeutics, Inc.'s moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 172% expanding the revenue base. The margin cascade from 100% gross to -140% operating to -117.2% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 37th percentile.
The margin profile shows gross margins of 100%, operating margins of -140%, net margins of -117.2%. Return metrics include ROE of -6.7% and ROA of -3.6%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -6.7% compares to a sector median of -2.5%.
The balance sheet reflects above-average leverage with D/E of 87%, revenue growth of 172%. The sector median D/E is 0%, putting Monte Rosa Therapeutics, Inc. at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Monte Rosa Therapeutics, Inc. ( NASDAQ:GLUE ) shares have retraced a considerable 26% in the last month, reversing a...
Key Insights Significantly high institutional ownership implies Monte Rosa Therapeutics' stock price is sensitive to...
In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including 2 patients with RECIST partial responses and 3 with stable disease, all showing reduction in size of target lesions Across all 15 evaluable patients, the overall RECIST disease control rate was 67%, and 10 of 15 patients showed tumor size reductions of target lesions Combination of MRT-2359 a
Despite a growing sentiment favoring industrial and dividend stocks in 2026, three high-risk stocks that surged over 100% in 2025 continue to show upside potential. FTAI Aviation benefits from GE Aerospace and Palantir partnerships, Kratos Defense gains from defense sector positioning, and Monte Rosa Therapeutics shows promise from positive clinical trial data. All three trade near or below analyst price targets with further upside expected.